This content is machine translated Perspectives for CRSwNP therapy. New approaches in the pipeline Currently, there are two approved biologics for the treatment of CRS and polyposis nasi: dupilumab and omalizumab. However, several other therapeutic options are currently in development, some of which are…
View Post 3 min This content is machine translated Off-label use of dupilumab 16-year-old can breathe again Physicians from the Department of Otorhinolaryngology at the University Hospital of Giessen and Marburg were dealing with a 16-year-old patient with a particularly pronounced chronic rhinosinusitis with nasal polyps (CRScNP)…
View Post 2 min This content is machine translated Dupilumab EU approval for severe chronic rhinosinusitis with polyposis nasi The monoclonal antibody dupilumab, which has already been approved by the European Medicines Agency (EMA) for the treatment of atopic dermatitis and asthma, is now also available for patients with…
